Table 4 Safety outcomes for the included studies
First Author | Groups | Patients with ≥ 1 TEAE, n (%) | Grade ≥ 3 TEAEs, n (%) | Serious TEAEs, n (%) | TEAEs leading to death, n (%) | TEAEs leading to discontinuation, n (%) | TEAEs leading to dose modification or treatment delays, n (%) |
|---|---|---|---|---|---|---|---|
Li et al. 2022 [18] | TS + CT CT | N/A N/A | N/A N/A | N/A N/A | N/A N/A | N/A N/A | N/A N/A |
Lu et al. 2021 [19] | TS + CT CT | 222 (100) 109 (99.1) | 150 (67.6) 59 (53.6) | 74 (33.3) 23 (20.9) | 7 (3.2) 2 (1.8) | 57 (25.7) 10 (9.1) | 149 (67.1) 57 (51.8) |
Wang et al. 2021 [20] | Arm A: TS + CT (PTX + CBP) Arm B: TS + CT (nab PTX + CBP) Arm C: CT (PTX + CBP) | 120 (100.0) 117 (99.2) 117 (100.0) | 106 (88.3) 102 (86.4) 98 (83.8) | 44 (36.7) 45 (38.1) 29 (24.8) | 4 (3.3) 5 (4.2) 5 (4.3) | 15 (12.5) 35 (29.7) 18 (15.4) | N/A N/A N/A |
Zhou et al. 2022 [21] | TS CT | 517 (96.8) 254 (98.4) | 225 (42.1) 193 (74.8) | 184 (34.5) 84 (32.6) | 34 (6.4) 12 (4.7) | 64 (12.0) 34 (13.2) | 125 (23.4) 96 (37.2) |